● Not Yet Recruiting

Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia

Condition: Cancer Cachexia Syndrome · Cancer Cachexia · Sponsor: Qilu Pharmaceutical Co., Ltd.

PhasePhase 1/Phase 2

Planned participants88

Who can joinAll sexes, 18 Years to 55 Years

Healthy volunteersYes

About this study

Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia

This description comes directly from the study's public registry record.

Talk to the study team

Li Zhang · 020-87343458 · zhangli@sysucc.org.cn

Yan Huang · 020-87343366 · huangyan@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun-Yat-sen University Cancer Center

Guangzhou, China

—

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07735104